Numab Therapeutics Completes Oversubscribed CHF 100 Million Series C Financing
Proceeds will be Used to Accelerate Advancement of Pipeline of Multispecific Antibodies in Oncology
26-May-2021 -
Numab Therapeutics AG, a clinical stage biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer and inflammation, announced the closing of a CHF 100 million (approximately USD 110 million) Series C financing. The financing was co-led by new ...
cancer
immunotherapies
inflammation
+1